Enomoto Yasunori, Takada Kazuto, Hagiwara Eri, Kojima Eiji
Division of Respiratory and Allergy Medicine, Komaki City Hospital, Komaki, 1-20, Johbushi, Komaki City 485-8520, Japan.
Respir Investig. 2013 Sep;51(3):153-7. doi: 10.1016/j.resinv.2013.02.004. Epub 2013 Mar 29.
The influence of epidermal growth factor receptor (EGFR) mutation status on distant and lymph node metastasis is not fully understood.
Ninety-five consecutive patients with stage IV lung adenocarcinoma, who had been examined for the EGFR mutation status, were retrospectively analyzed with regard to numbers of distant metastasis and clinical stage of lymph node metastasis at the time of diagnosis.
While EGFR mutation status did not influence the presence or absence of distant metastasis in the lung, brain, or liver, patients with EGFR mutations demonstrated a significantly greater number of metastatic lesions in the lung (median: 85 vs. 4, P=0.01) and the brain (11 vs. 3.5, P=0.04). On the other hand, patients with EGFR mutations showed a significantly lower lymph node staging (P<0.01).
The presence of EGFR mutations in patients with lung adenocarcinoma correlates with lower lymph node stage and a greater number of metastatic lesions in the lung and brain.
表皮生长因子受体（EGFR）突变状态对远处转移和淋巴结转移的影响尚未完全明确。
回顾性分析95例连续的IV期肺腺癌患者，这些患者均已检测EGFR突变状态，分析其诊断时远处转移数量和淋巴结转移临床分期。
虽然EGFR突变状态不影响肺、脑或肝远处转移的有无，但EGFR突变患者肺部（中位数：85对4，P = 0.01）和脑部（11对3.5，P = 0.04）的转移病灶数量明显更多。另一方面，EGFR突变患者的淋巴结分期明显更低（P<0.01）。
肺腺癌患者中EGFR突变的存在与较低的淋巴结分期以及肺和脑转移病灶数量增加相关。
